Considering that HK2 and STING expressing macrophages are abundant in sepsis and are associated with drastic inflammation, we developed a novel immunomodulating agent referred to as LDO, which links glycolysis inhibitor LND with STING inhibitor 4-OI to achieve the dual inhibition of HK2 and STING (Fig. 3A). The gene discussed is STING1; the disease is Sepsis.